Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era

2019 ◽  
Vol 60 (11) ◽  
pp. 2679-2688 ◽  
Author(s):  
Fei Qi ◽  
Bo Chen ◽  
Jingjing Wang ◽  
Xinyi Lin ◽  
Shunan Qi ◽  
...  
Keyword(s):  
T Cell ◽  
High Risk ◽  
Cell Lymphoma ◽  
Early Stage ◽  
T Cell Lymphoma ◽  
Sequential Treatment ◽  
Treatment Modalities ◽  
Nasal Type ◽  
Nk T Cell ◽  
Modern Era

scholarly journals First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG

2020 ◽  
Vol 4 (13) ◽  
pp. 3141-3153
Author(s):  
Shu-Nan Qi ◽  
Yong Yang ◽  
Yu-Qin Song ◽  
Ying Wang ◽  
Xia He ◽  
...  
Keyword(s):  
T Cell ◽  
Survival Benefit ◽  
Cell Lymphoma ◽  
Early Stage ◽  
T Cell Lymphoma ◽  
Collaborative Group ◽  
First Line ◽  
Early Stage Disease ◽  
Nasal Type ◽  
Nk T Cell

Abstract The present study investigated the survival benefit of non–anthracycline (ANT)-based vs ANT-based regimens in a large-scale, real-world cohort of patients with extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTCL). Within the China Lymphoma Collaborative Group (CLCG) database (2000-2015), we identified 2560 newly diagnosed patients who received chemotherapy with or without radiotherapy. Propensity score matching (PSM) and multivariable analyses were used to compare overall survival (OS) and progression-free survival (PFS) between the 2 chemotherapy regimens. We explored the survival benefit of non–ANT-based regimens in patients with different treatments in early-stage disease and in risk-stratified subgroups. Non–ANT-based regimens significantly improved survivals compared with ANT-based regimens. The 5-year OS and PFS were 68.9% and 59.5% for non–ANT-based regimens compared with 57.5% and 44.5% for ANT-based regimens in the entire cohort. The clinical advantage of non–ANT-based regimens was substantial across the subgroups examined, regardless of stage and risk-stratified subgroup, and remained significant in early-stage patients who received radiotherapy. The survival benefits of non–ANT-based regimens were consistent after adjustment using multivariable and PSM analyses. These findings provide additional evidence supporting non–ANT-based regimens as a first-line treatment of patients with ENKTCL.

scholarly journals Unfavorable prognosis of elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma

2011 ◽  
Vol 22 (2) ◽  
pp. 390-396 ◽  
Author(s):  
Z.Y. Wang ◽  
Y.X. Li ◽  
H. Wang ◽  
W.H. Wang ◽  
J. Jin ◽  
...  
Keyword(s):  
T Cell ◽  
Elderly Patients ◽  
Cell Lymphoma ◽  
Early Stage ◽  
T Cell Lymphoma ◽  
Nasal Type ◽  
Nk T Cell

scholarly journals Optimizing Radiation Dose for Early-Stage Extranodal Nasal-Type NK/T-Cell Lymphoma

2016 ◽  
Vol 96 (2) ◽  
pp. S166-S167
Author(s):  
Y. Yang ◽  
J. Wu ◽  
T. Wu ◽  
S.Y. Zhu ◽  
L.T. Qian ◽  
...  
Keyword(s):  
T Cell ◽  
Radiation Dose ◽  
Cell Lymphoma ◽  
Early Stage ◽  
T Cell Lymphoma ◽  
Nasal Type ◽  
Nk T Cell
Sign in / Sign up

Export Citation Format

Share Document